{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T05:20:56Z","timestamp":1739424056588,"version":"3.37.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2002,3]]},"DOI":"10.1007\/bf03165138","type":"journal-article","created":{"date-parts":[[2009,9,30]],"date-time":"2009-09-30T07:15:00Z","timestamp":1254294900000},"page":"296-304","source":"Crossref","is-referenced-by-count":3,"title":["The therapy of myelofibrosis: Targeting pathogenesis"],"prefix":"10.1007","volume":"76","author":[{"given":"Ruben A.","family":"Mesa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF03165138_CR1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2141.1994.tb04723.x","volume":"86","author":"N Tsukamoto","year":"1994","unstructured":"Tsukamoto N, Morita K, Maehara T, et al. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement [see comments].Br J Haematol. 1994;86:253\u2013258.","journal-title":"Br J Haematol."},{"key":"BF03165138_CR2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","volume":"342","author":"A Tefferi","year":"2000","unstructured":"Tefferi A. Myelofibrosis with myeloid metaplasia.N Engl J Med. 2000;342:1255\u20131265.","journal-title":"N Engl J Med."},{"key":"BF03165138_CR3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I","volume":"61","author":"RA Mesa","year":"1999","unstructured":"Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976\u20131995.Am J Hematol. 1999;61:10\u201315.","journal-title":"Am J Hematol."},{"key":"BF03165138_CR4","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","volume":"88","author":"B Dupriez","year":"1996","unstructured":"Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system [see comments].Blood. 1996;88:1013\u20131018.","journal-title":"Blood."},{"key":"BF03165138_CR5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0369-8114(00)00020-1","volume":"49","author":"F Cervantes","year":"2001","unstructured":"Cervantes F. Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000.Pathol Biol (Paris). 2001;49:148\u2013152.","journal-title":"Pathol Biol (Paris)."},{"key":"BF03165138_CR6","first-page":"658","volume":"2","author":"M Buschle","year":"1988","unstructured":"Buschle M, Janssen JW, Drexler H, Lyons J, Anger B, Bartram CR. Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation.Leukemia. 1988;2:658\u2013660.","journal-title":"Leukemia."},{"key":"BF03165138_CR7","first-page":"258","volume":"4","author":"B Anger","year":"1990","unstructured":"Anger B, Janssen JW, Schrezenmeier H, Hehlmann R, Heimpel H, Bartram CR. Clonal analysis of chronic myeloproliferative disorders using X-linked DNA polymorphisms.Leukemia. 1990;4:258\u2013261.","journal-title":"Leukemia."},{"key":"BF03165138_CR8","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1046\/j.1365-2141.1997.3073124.x","volume":"98","author":"P Guardiola","year":"1997","unstructured":"Guardiola P, Esperou H, Cazalshatem D, et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia.Br J Haematol. 1997;98:1004\u20131009.","journal-title":"Br J Haematol."},{"key":"BF03165138_CR9","first-page":"2831","volume":"93","author":"P Guardiola","year":"1999","unstructured":"Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study.Blood. 1999;93:2831\u20132838.","journal-title":"Blood."},{"key":"BF03165138_CR10","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/blood.V98.3.586","volume":"98","author":"JE Anderson","year":"2001","unstructured":"Anderson JE, Tefferi A, Craig F, et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis.Blood. 2001;98:586\u2013593.","journal-title":"Blood."},{"key":"BF03165138_CR11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-0609.1999.tb01738.x","volume":"62","author":"MD Colovic","year":"1999","unstructured":"Colovic MD, Wiernik PH, Jankovic GM, Vidovic AD, Janosevic S, Basara NM. Circulating haemopoietic progenitor cells in primary and secondary myelofibrosis: relation to collagen and reticulin fibrosis.European J Haematol., 1999;62:155\u2013159.","journal-title":"European J Haematol."},{"key":"BF03165138_CR12","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1182\/blood.V98.12.3249","volume":"98","author":"G Barosi","year":"2001","unstructured":"Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34 (+) cells in myelofibrosis with myeloid metaplasia.Blood. 2001;98:3249\u20133255.","journal-title":"Blood."},{"key":"BF03165138_CR13","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1182\/blood.V97.11.3665","volume":"97","author":"RA Mesa","year":"2001","unstructured":"Mesa RA, Li CY, Schroeder G, Tefferi A. Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia.Blood. 2001;97:3665\u20133667.","journal-title":"Blood."},{"key":"BF03165138_CR14","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","volume":"95","author":"A Tefferi","year":"2000","unstructured":"Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.Blood. 2000;95:2226\u20132233.","journal-title":"Blood."},{"key":"BF03165138_CR15","first-page":"a3228","volume":"96","author":"WA Houck","year":"2000","unstructured":"Houck WA, Mesa RA, Tefferi A. Antemortem presentation and management of non-hepatosplenic extramedullary hematopoiesis in myelofibrosis with myeloid metaplasia.Blood. 2000;96:a3228.","journal-title":"Blood."},{"key":"BF03165138_CR16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1600-0609.1988.tb00212.x","volume":"41","author":"E Lofvenberg","year":"1988","unstructured":"Lofvenberg E, Wahlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea.Eur J Haematol. 1988;41:375\u2013381.","journal-title":"Eur J Haematol."},{"key":"BF03165138_CR17","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","volume":"332","author":"S Cortelazzo","year":"1995","unstructured":"Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.N Engl J Med. 1995;332:1132\u20131136.","journal-title":"N Engl J Med."},{"key":"BF03165138_CR18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.7326\/0003-4819-128-1-199801010-00005","volume":"128","author":"PJ Best","year":"1998","unstructured":"Best PJ, Daoud MS, Pittelkow MR, Petitt RM. Hydroxyurea-induced leg ulceration in 14 patients [see comments].Ann Inter Med. 1998;128:29\u201332.","journal-title":"Ann Inter Med."},{"key":"BF03165138_CR19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/(SICI)1096-8652(199605)52:1<42::AID-AJH7>3.0.CO;2-6","volume":"52","author":"S Nand","year":"1996","unstructured":"Nand S, Stock W, Godwin J, Fisher SG. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.Am J Hematol. 1996;52:42\u201346.","journal-title":"Am J Hematol."},{"key":"BF03165138_CR20","first-page":"808","volume":"58","author":"CP Dinney","year":"1998","unstructured":"Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration.Cancer Res. 1998;58:808\u2013814.","journal-title":"Cancer Res."},{"key":"BF03165138_CR21","first-page":"40","volume":"34","author":"RT Silver","year":"1997","unstructured":"Silver RT. Interferon alfa: effects of long-term treatment for polycythemia vera.Semin Hematol. 1997;34:40\u201350.","journal-title":"Semin Hematol."},{"key":"BF03165138_CR22","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1182\/blood.V97.6.1896","volume":"97","author":"A Tefferi","year":"2001","unstructured":"Tefferi A, Elliot MA, Yoon SY, et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia.Blood. 2001;97:1896.","journal-title":"Blood."},{"key":"BF03165138_CR23","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.1365-2141.2000.02161.x","volume":"110","author":"A Micouin","year":"2000","unstructured":"Micouin A, Steunou V, Wietzerbin J, Martyre MC. Lack of interferon-alpha-induced tyrosine phosphorylation of Vav protooncogene in patients with myelofibrosis with myeloid metaplasia.Br J Haematol. 2000;110:362\u2013369.","journal-title":"Br J Haematol."},{"key":"BF03165138_CR24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.onc.1203314","volume":"19","author":"A Micouin","year":"2000","unstructured":"Micouin A, Wietzerbin J, Steunou V, Martyre MC. p95(vav) associates with the type I interferon (IFN) receptor and contributes to the antiproliferative effect of IFN-alpha in megakaryocytic cell lines.Oncogene. 2000;19:387\u2013394.","journal-title":"Oncogene."},{"key":"BF03165138_CR25","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8","volume":"83","author":"HS Gilbert","year":"1998","unstructured":"Gilbert HS. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy.Cancer. 1998;83:1205\u20131213.","journal-title":"Cancer."},{"key":"BF03165138_CR26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.0954-6820.1964.tb00605.x","volume":"175","author":"M Jensen","year":"1964","unstructured":"Jensen M. Splenectomy in myelofibrosis.Acta Medica Scandinavica. 1964;175:533\u2013544.","journal-title":"Acta Medica Scandinavica."},{"key":"BF03165138_CR27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1054\/blre.2000.0132","volume":"14","author":"RA Mesa","year":"2000","unstructured":"Mesa RA, Elliott MA, Tefferi A. Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia.Blood Rev. 2000;14:121\u2013129.","journal-title":"Blood Rev."},{"key":"BF03165138_CR28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000204888","volume":"85","author":"A Lopez-Guillermo","year":"1991","unstructured":"Lopez-Guillermo A, Cervantes F, Bruguera M, Pereira A, Feliu E, Rozman C. Liver dysfunction following, splenectomy in idiopathic myelofibrosis: a study of 10 patients.Acta Haematologica. 1991;85:184\u2013188.","journal-title":"Acta Haematologica."},{"key":"BF03165138_CR29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1365-2141.1998.00998.x","volume":"103","author":"MA Elliott","year":"1998","unstructured":"Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia.Br J Haematol. 1998; 103:505\u2013511.","journal-title":"Br J Haematol."},{"key":"BF03165138_CR30","doi-asserted-by":"crossref","unstructured":"Tefferi A, Jimenez T, Gray L, Mesa R, Chen M. Radiation Therpay for Symptomatic Hepatomegaly in Myelofibrosis with Myeloid Metaplasia.Eur J Hematol. 2001;in press.","DOI":"10.1034\/j.1600-0609.2001.00342.x"},{"key":"BF03165138_CR31","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0145-2126(00)00018-7","volume":"24","author":"R Bouabdallah","year":"2000","unstructured":"Bouabdallah R, Coso D, Gonzague-Casabianca L, Alzieu C, Resbeut M, Gastaut JA. Safety and efficacy of splenic irradiation in the treatment of patients with idiopathic myelofibrosis: a report on 15 patients.Leuk Res. 2000;24:491\u2013495.","journal-title":"Leuk Res."},{"key":"BF03165138_CR32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1378\/chest.120.3.801","volume":"120","author":"D Dingli","year":"2001","unstructured":"Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders.Chest. 2001;120:801\u2013808.","journal-title":"Chest."},{"key":"BF03165138_CR33","doi-asserted-by":"crossref","unstructured":"Steensma DP, Hook CC, Stafford SL, Tefferi A. Low-dose, single-fraction, whole lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia.Br J Haematol. 2002; (In Press).","DOI":"10.1046\/j.1365-2141.2002.03695.x"},{"key":"BF03165138_CR34","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/0002-9343(88)90130-1","volume":"84","author":"A Grieco","year":"1988","unstructured":"Grieco A, Manna R, Mancini R, Gambassi G. Massive hepatomegaly following splenectomy for myeloid metaplasia.Am J Med. 1988;84:797.","journal-title":"Am J Med."},{"key":"BF03165138_CR35","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1046\/j.1365-2141.1997.3843198.x","volume":"99","author":"A Tefferi","year":"1997","unstructured":"Tefferi A, Silverstein MN, Li CY. 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia [see comments].Br J Haematol. 1997;99:352\u2013357.","journal-title":"Br J Haematol."},{"key":"BF03165138_CR36","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.1998.0847c.x","volume":"102","author":"N Abramson","year":"1998","unstructured":"Abramson N, Marks AR. Effect of 2-CDA on thrombocytopenia in myelofibrosis [letter; comment].Br J Haematol. 1998;102:631\u2013632.","journal-title":"Br J Haematol."},{"key":"BF03165138_CR37","first-page":"616","volume":"83","author":"JN Rodriguez","year":"1998","unstructured":"Rodriguez JN, Martino ML, Dieguez JC, Prados D. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach.Haematologica. 1998;83:616\u2013621.","journal-title":"Haematologica."},{"key":"BF03165138_CR38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/1097-0142(19820115)49:2<308::AID-CNCR2820490217>3.0.CO;2-4","volume":"49","author":"E Besa","year":"1982","unstructured":"Besa E, Nowell P, Geller N, GArdner F. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in prediciting response and survival.Cancer. 1982;49:308.","journal-title":"Cancer."},{"key":"BF03165138_CR39","first-page":"595","volume":"85","author":"F Cervantes","year":"2000","unstructured":"Cervantes F, Hernandez-Boluda JC, Alvarez A, Nadal E, Montserrat E. Danazol treatment of idiopathic myelofibrosis with severe anemia.Haematologica. 2000;85:595\u2013599.","journal-title":"Haematologica."},{"key":"BF03165138_CR40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/(SICI)1096-8652(199612)53:4<239::AID-AJH5>3.0.CO;2-Z","volume":"53","author":"V Levy","year":"1996","unstructured":"Levy V, Bourgarit A, Delmer A, et al. Treatment of Agnogenic Myeloid Metaplasia With Danazol \u2014 a Report of Four Cases.Am J Hematol. 1996;53:239\u2013241.","journal-title":"Am J Hematol."},{"key":"BF03165138_CR41","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D\u2019Amato","year":"1994","unstructured":"D\u2019Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis.Proc Natl Acad Sci USA. 1994;91:4082\u20134085.","journal-title":"Proc Natl Acad Sci USA."},{"key":"BF03165138_CR42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00001813-199605000-00015","volume":"7","author":"AI Minchinton","year":"1996","unstructured":"Minchinton AI, Fryer KH, Wendt KR, Clow KA, Hayes MM. The effect of thalidomide on experimental tumors and metastases.Anti Cancer Drugs. 1996;7:339\u2013343.","journal-title":"Anti Cancer Drugs."},{"key":"BF03165138_CR43","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1993","unstructured":"Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [see comments].N Engl J Med. 1993;341:1565\u20131571.","journal-title":"N Engl J Med."},{"key":"BF03165138_CR44","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1365-2141.2001.02918.x","volume":"114","author":"G Barosi","year":"2001","unstructured":"Barosi G, Grossi A, Comotti, B, Musto P, Gamba G, Marchetti M. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.Br J Haematol. 2001;114:78\u201383.","journal-title":"Br J Haematol."},{"key":"BF03165138_CR45","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2141.2001.03072.x","volume":"115","author":"L Canepa","year":"2001","unstructured":"Canepa L, Ballerini F, Varaldo R, et al. Thalidomide in agnogenic and secondary myelofibrosis.Br J Haematol. 2001;115:313\u2013315.","journal-title":"Br J Haematol."},{"key":"BF03165138_CR46","doi-asserted-by":"crossref","unstructured":"Elliott MA, Mesa RA, Li C-Y, et al. Thalidomide Treatment in Myelofibrosis with Myeloid Metaplasia.Br J Haematol. (in press). 2002.","DOI":"10.1046\/j.1365-2141.2002.03443.x"},{"key":"BF03165138_CR47","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1182\/blood.V96.12.4007","volume":"96","author":"A Tefferi","year":"2000","unstructured":"Tefferi A, Elliott. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia.Blood. 2000;96:4007.","journal-title":"Blood."},{"key":"BF03165138_CR48","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood.V97.8.2527","volume":"97","author":"MC Kyrtsonis","year":"2001","unstructured":"Kyrtsonis MC, Kokoris SI, Kontopidou FN, Siakantaris MP, Kittas C, Pangalis GA. Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undertermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody.Blood. 2001;97:2527\u20132528.","journal-title":"Blood."},{"key":"BF03165138_CR49","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.4049\/jimmunol.154.11.6040","volume":"154","author":"EJ Battegay","year":"1995","unstructured":"Battegay EJ, Raines EW, Colbert T, Ross R. TNF-alpha stimulation of fibroblast proliferation. Dependence on plateletderived growth factor (PDGF) secretion and alteration of PDGF receptor expression.J Immunol. 1995;154:6040\u20136047.","journal-title":"J Immunol."},{"key":"BF03165138_CR50","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood.V85.4.989.bloodjournal854989","volume":"85","author":"LS Rusten","year":"1995","unstructured":"Rusten LS, Jacobsen SE. Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors.Blood. 1995;85:989\u2013996.","journal-title":"Blood."},{"key":"BF03165138_CR51","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1084\/jem.163.6.1433","volume":"163","author":"CA Dinarello","year":"1986","unstructured":"Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin), is an endogenous pyrogen and induces production of interleukin 1.J Exp Med. 1986;163:1433\u20131450.","journal-title":"J Exp Med."},{"key":"BF03165138_CR52","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1182\/blood.V99.6.2252","volume":"99","author":"DP Steensma","year":"2002","unstructured":"Steensma DP, Mesa RA, Li CY, Gray L, Tefferi A. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study.Blood. 2002;99:2252\u20132254.","journal-title":"Blood."},{"key":"BF03165138_CR53","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.N Engl J Med. 2001;344:1031\u20131037.","journal-title":"N Engl J Med."},{"key":"BF03165138_CR54","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","volume":"96","author":"MC Heinrich","year":"2000","unstructured":"Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.Blood. 2000;96:925\u2013932.","journal-title":"Blood."},{"key":"BF03165138_CR55","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1073\/pnas.92.7.2558","volume":"92","author":"E Buchdunger","year":"1995","unstructured":"Buchdunger E, Zimmermann J, Mett H, et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.Proc Natl Acad Sci USA. 1995;92:2558\u20132562.","journal-title":"Proc Natl Acad Sci USA."},{"key":"BF03165138_CR56","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1182\/blood-2001-12-0154","volume":"99","author":"A Tefferi","year":"2002","unstructured":"Tefferi A, Mesa RA, Gray LA, et al. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia.Blood. 2002;99:3854\u20133856.","journal-title":"Blood."},{"key":"BF03165138_CR57","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1056\/NEJM200202283460919","volume":"346","author":"MA Elliott","year":"2002","unstructured":"Elliott MA, Mesa RA, Tefferi A. Adverse events after imatinib mesylate therapy.N Engl J Med. 2002;346:712\u2013713.","journal-title":"N Engl J Med."},{"key":"BF03165138_CR58","first-page":"L311","volume":"276","author":"G Gurujeyalakshmi","year":"1999","unstructured":"Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level.Am J Physiol. 1999;276:L311-L318.","journal-title":"Am J Physiol."},{"key":"BF03165138_CR59","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0192-0561(98)00042-3","volume":"20","author":"WC Cain","year":"1998","unstructured":"Cain WC, Stuart RW, Lefkowitz DL, Starnes JD, Margolin S, Lefkowitz SS. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone.Int J Immunopharmacol. 1998;20:685\u2013695.","journal-title":"Int J Immunopharmacol."},{"key":"BF03165138_CR60","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-3565(24)35110-9","volume":"291","author":"SN Iyer","year":"1999","unstructured":"Iyer SN, Gurujeyalakshmi G, Giri, SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.J Pharmacol Exp Ther. 1999;291:367\u2013373.","journal-title":"J Pharmacol Exp Ther."},{"key":"BF03165138_CR61","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1164\/ajrccm.159.4.9805017","volume":"159","author":"G Raghu","year":"1999","unstructured":"Raghu G, Johnson, WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study.Am J Respir Crit Care Med. 1999;159:1061\u20131069.","journal-title":"Am J Respir Crit Care Med."},{"key":"BF03165138_CR62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2141.2001.02883.x","volume":"114","author":"RA Mesa","year":"2001","unstructured":"Mesa RA, Tefferi A, Elliott MA, et al. A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia.Br J Haematol. 2001;114;111\u2013113.","journal-title":"Br J Haematol."},{"key":"BF03165138_CR63","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1600-0609.1984.tb00724.x","volume":"33","author":"A Manoharan","year":"1984","unstructured":"Manoharan A, Pitney WR. Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis.Scand J Haematol. 1984;33:453\u2013459.","journal-title":"Scand J Haematol."},{"key":"BF03165138_CR64","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1136\/bmj.2.6101.1513","volume":"2","author":"H Stott","year":"1977","unstructured":"Stott H, Fox W, Girling DJ, Stephens RJ, Galton DA. Acute leukaemia after busulphan.Br Med J. 1977;2:1513\u20131517.","journal-title":"Br Med J."},{"key":"BF03165138_CR65","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000204873","volume":"85","author":"F Cervantes","year":"1991","unstructured":"Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients.Acta Haematologica. 1991;85:124\u2013127.","journal-title":"Acta Haematologica."},{"key":"BF03165138_CR66","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.0007-1048.2001.03331.x","volume":"116","author":"MC Petti","year":"2002","unstructured":"Petti MC, Latagliata R, Spadea T, et al. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.Br J Haematol. 2002;116:576\u2013581.","journal-title":"Br J Haematol."},{"key":"BF03165138_CR67","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1182\/blood.V99.6.2255","volume":"99","author":"SM Devine","year":"2002","unstructured":"Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.Blood. 2002;99:2255\u20132258.","journal-title":"Blood."},{"key":"BF03165138_CR68","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood.V97.11.3361","volume":"97","author":"JE Karp","year":"2001","unstructured":"Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.Blood. 2001;97:3361\u20133369.","journal-title":"Blood."},{"key":"BF03165138_CR69","doi-asserted-by":"crossref","first-page":"a1963","DOI":"10.1182\/blood.V98.6.1963","volume":"98","author":"RA Mesa","year":"2001","unstructured":"Mesa RA, Tefferi A, Gray L, Schroeder G, Kaufmann SH The farnesyltransferase inhibitor, R115777, has significant in vitro activity in myelofibrosis with myeloid metaplasia.Blood. 2001;98:a1963.","journal-title":"Blood."},{"key":"BF03165138_CR70","first-page":"a3032","volume":"98","author":"D Thomas","year":"2001","unstructured":"Thomas D, Cortes J, O\u2019Brien SM, et al. R115777, a Farnesyl Transferase Inhibitor (FTI), has significant anti-leukemia activity in patients with chronic myeloid leukemia (CML).Blood. 2001;98:a3032.","journal-title":"Blood."},{"key":"BF03165138_CR71","first-page":"772","volume":"86","author":"G Pozzato","year":"2001","unstructured":"Pozzato G, Zorat F, Nascimben F, Comar C, Kikic F, Festini G. Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia.Haematologica. 2001;86:772\u2013773.","journal-title":"Haematologica."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03165138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03165138\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03165138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T12:40:30Z","timestamp":1739364030000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03165138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":71,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["BF03165138"],"URL":"https:\/\/doi.org\/10.1007\/bf03165138","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2002,3]]}}}